-
摘要: 心力衰竭(心衰)已成为威胁人类健康的重要原因之一，随着我国经济的不断增长以及人口老龄化的加剧，心血管疾病成为我国过早发病和死亡的主要原因。目前终末期心力衰竭患者最成熟有效的治疗方案是心脏移植，但由于供体器官严重短缺，能接受心脏移植的患者很少。目前已经提出了几种解决方案来应对供体心脏短缺危机，心室辅助装置成为最有希望的替代方案之一。Abstract: Heart failure has become one of the important causes threatening human health. With the continuous growth of Chinese economy and the aggravation of population aging, cardiovascular disease has become the main cause of premature morbidity and death in China. At present, the most mature and effective treatment for patients with end-stage heart failure is heart transplantation, but due to the severe shortage of donor organs, few patients can receive heart transplants. Several solutions have been proposed to deal with the shortage of donor hearts, ventricular assist device as the most promising alternatives.
-
Key words:
- ventricular assist device /
- end-stage heart failure
-
-
[1] 中国心血管健康与疾病报告2021概要[J]. 心脑血管病防治, 2022, 22: 20-36, 40.
[2] Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association[J]. Circulation, 2023, 147(8): e93-e621.
[3] Gerhard EF, Wang L, Singh R, et al. LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events[J]. J Heart Lung Transplant, 2021, 40(12): 1560-1570. doi: 10.1016/j.healun.2021.08.001
[4] Burkhoff D, Topkara VK, Sayer G, et al. Reverse remodeling with left ventricular assist devices[J]. Circ Res, 2021, 128(10): 1594-1612. doi: 10.1161/CIRCRESAHA.121.318160
[5] Geller BJ, Sinha SS, Kapur NK, et al. Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock: a scientific statement from the American Heart Association[J]. Circulation, 2022, 146(6): e50-e68. http://pubmed.ncbi.nlm.nih.gov/35862152/
[6] van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association[J]. Circulation, 2017, 136(16): e232-e268. http://www.researchgate.net/profile/Ahmet_Kilic3/publication/319906203_Contemporary_Management_of_Cardiogenic_Shock_A_Scientific_Statement_From_the_American_Heart_Association/links/5a173768a6fdcc50ade60c4c/Contemporary-Management-of-Cardiogenic-Shock-A-Scientific-Statement-From-the-American-Heart-Association.pdf
[7] Combes A, Price S, Slutsky AS, et al. Temporary circulatory support for cardiogenic shock[J]. Lancet, 2020, 396(10245): 199-212. doi: 10.1016/S0140-6736(20)31047-3
[8] Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention[J]. J Am Coll Cardiol, 2015, 65(19): e7-e26.
[9] Omerovic EE. Intraaortic balloon support for myocardial infarction with cardiogenic shock[J]. Euro J Heart Fail, 2019, 21: 449-450. doi: 10.1002/ejhf.1381
[10] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail, 2016, 18(8): 891-975.
[11] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2018, 39(2): 119-177. http://www.vszek.hu/documents/Dokumentumtár%20(magyar)/Oktatás/kardiológia/Előadások/Guidelineok/12stemiescgl.pdf
[12] Schrage B, Schneider S, Zeymer U, et al. Response by schrage et al to letter regarding article, "impella support for acute myocardial infarction complicated by cardiogenic shock: a matched-pair IABP-SHOCK Ⅱ Trial 30-Day Mortality Analysis"[J]. Circulation, 2019, 140(11): e559-e560. http://pubmed.ncbi.nlm.nih.gov/31498699/
[13] Takeda K, Garan AR, Ando M, et al. Minimally invasive CentriMag ventricular assist device support integrated with extracorporeal membrane oxygenation in cardiogenic shock patients: a comparison with conventional CentriMag biventricular support configuration[J]. Eur J Cardiothorac Surg, 2017, 52(6): 1055-1061. doi: 10.1093/ejcts/ezx189
[14] Li P, Wu T, Hsu PL, et al. 30-day in vivo study of a fully maglev extracorporeal ventricular assist device[J]. Artif Organs, 2022, 46(11): 2171-2178. doi: 10.1111/aor.14317
[15] Li P, Wu L, Dong N. First experience of magnetically levitated extracorporeal left ventricular assist device for cardiogenic shock in China[J]. ESC Heart Fail, 2022, 9(2): 1471-1473. doi: 10.1002/ehf2.13769
[16] Li P, Zhang X, Chen S, et al. Case report: Successful percutaneous extracorporeal magnetic levitation ventricular assist device support in a patient with left heart failure due to dilated cardiomyopathy[J]. Front Cardiovasc Med, 2023, 10: 1093794. doi: 10.3389/fcvm.2023.1093794
[17] Molina EJ, Shah P, Kiernan MS, et al. The society of thoracic surgeons intermacs 2020 Annual Report[J]. Ann Thorac Surg, 2021, 111(3): 778-792. http://www.xueshufan.com/publication/3119194994
[18] Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 Randomized Trial[J]. JAMA, 2022, 328(12): 1233-1242.
-
计量
- 文章访问数: 976
- PDF下载数: 269
- 施引文献: 0
下载: